1. Scope

What is covered:

• Whole-diet patterns with hard-outcome data (Mediterranean, low-fat, plant-based).
• Food-group and macronutrient interventions relevant to healthy ageing (dietary fibre and whole grains, protein and skeletal muscle ageing, ultra-processed foods).
• Timing and restriction strategies marketed as “longevity” interventions: caloric restriction (CR), intermittent fasting (IF) and time-restricted eating (TRE).
• Emerging/experimental nutritional supplements promoted for ageing: NAD⁺ precursors (nicotinamide riboside [NR], nicotinamide mononucleotide [NMN]), spermidine, and amino-acid/mTOR modulation.
• Selected micronutrient supplementation with large RCT data (vitamin D, marine omega-3).

What is NOT covered:

• Clinical management of established malnutrition, eating disorders, enteral/parenteral nutrition, or disease-specific therapeutic diets (e.g. renal, coeliac).
• Weight-loss pharmacotherapy and bariatric surgery.
• Paediatric nutrition and nutrition in pregnancy beyond safety flags.

Framing: All content is adjunctive to conventional care. Where an intervention is off-label, experimental, research-only or expert-consensus, this is stated explicitly. Surrogate ageing biomarkers (telomere length, epigenetic clocks) are NOT treated as validated proxies for clinical benefit.

---

2. Background and pathophysiology

Biological rationale. Diet influences most recognised hallmarks of ageing — deregulated nutrient sensing, mitochondrial dysfunction, chronic inflammation (“inflammaging”), cellular senescence, and loss of proteostasis. The best-established, human-relevant mechanistic chain runs through cardiometabolic risk: visceral adiposity drives senescence, adipokine and inflammatory signalling, insulin resistance and accelerated vascular ageing, and weight loss in overweight/obese adults lowers inflammatory biomarkers and improves glycaemic control (JACC geroscience scientific statement, Forman et al., 2023).

Key mechanisms plausibly targeted by nutrition:

• Nutrient sensing (mTOR, AMPK, IGF-1, GCN2): protein/amino-acid availability (especially leucine and methionine) modulates mTOR; energy restriction activates AMPK and autophagy (Gallinetti et al., 2013; Kim et al., 2025).
• Metabolic switching / ketogenesis: fasting periods shift fuel use from hepatic glucose to adipose-derived ketones, activating stress-resistance and repair pathways (de Cabo & Mattson, NEJM 2019).
• Circadian/peripheral clock alignment: meal timing acts as a peripheral zeitgeber; misalignment is epidemiologically linked to cardiometabolic disease (AHA scientific statement, Knutson et al., 2025).
• NAD⁺ metabolism: tissue NAD⁺ declines with age; precursor supplementation aims to restore it (Bhasin et al., 2023).

Robust human mechanistic evidence. The strongest human data are for improvements in intermediate cardiometabolic phenotypes (LDL-C, blood pressure, insulin sensitivity, body composition, inflammatory markers) with dietary patterns, fibre, and restriction strategies (Reynolds et al., Lancet 2019; de Cabo & Mattson, 2019; Minari & Pisani, 2026). These are surrogate endpoints and should not be equated with lifespan/healthspan extension unless linked to hard outcomes.

Preclinical only (clearly separated — do not extrapolate to patients):

• CR extends median lifespan by ~14–45% in rats and ~4–27% in mice, with strain- and sex-dependent variation and even lifespan shortening in some strains; two landmark primate CR studies gave discordant survival results (de Cabo & Mattson, 2019).
• Methionine restriction (~40% lifespan extension), tryptophan restriction (~23%) and leucine restriction extend rodent lifespan via mTOR/GCN2 pathways (Santos et al., 2015; Wang et al., 2022) — no equivalent human longevity data.
• NAD⁺ augmentation improves metabolic, mitochondrial and functional outcomes across rodent models with inconsistent effects (Gallagher & Emmanuel, 2026).

---

3. Evidence base and grading

Evidence types available range from large individual-participant meta-analyses of RCTs and prospective cohorts (dietary patterns, fibre, UPFs) down to small, short, surrogate-endpoint RCTs (TRE, NAD⁺ precursors, spermidine). Hard clinical outcomes (all-cause and cause-specific mortality, MI, stroke, incident type 2 diabetes, sarcopenia/frailty) are available for whole-diet patterns and food groups; for restriction timing and “anti-ageing” supplements, outcomes are almost entirely surrogate.

GRADE-style summary of major outcomes

Intervention → Outcome	Evidence statement	Certainty (GRADE)	Recommendation
Mediterranean dietary programme → all-cause & CV mortality, stroke, non-fatal MI (higher-risk adults)	Network meta-analysis, 40 RCTs, n≈35,548: all-cause mortality OR 0.72 (0.56–0.92), CV mortality OR 0.55 (0.39–0.78), stroke OR 0.65 (0.46–0.93), non-fatal MI OR 0.48 (0.36–0.65) (Karam et al., BMJ 2023)	Moderate	Strong recommendation
Low-fat dietary programme → all-cause mortality, non-fatal MI	Same NMA: all-cause mortality OR 0.84 (0.74–0.95); non-fatal MI OR 0.77 (0.61–0.96); no convincing difference vs Mediterranean	Moderate	Strong recommendation (equivalent option)
Higher Mediterranean adherence → all-cause mortality (general adults)	54 cohorts, n≈1.83M: RR 0.96 (0.95–0.97) per 1-point adherence increase	Moderate	Strong recommendation
Healthy plant-based pattern → T2D, CVD, cancer, mortality	76 cohorts, n≈2.23M: mortality RR 0.84 (0.78–0.92); T2D 0.82; CVD 0.90; cancer 0.91 (healthful PDI stronger; unhealthful PDI harmful)	Low–Moderate (observational, heterogeneity)	Conditional recommendation
Dietary fibre 25–29 g/day & whole grains → all-cause/CV mortality, CHD, T2D	Lancet series (Reynolds 2019) + cohort meta-analyses: fibre all-cause mortality HR ~0.77; whole grains ~13–33% risk reductions; dose-response, linear; supported by RCTs on weight/lipids/BP	Moderate	Strong recommendation
Ultra-processed foods (high vs low) → mortality, CVD, T2D	Umbrella review (Lane et al., BMJ 2024): all-cause mortality RR 1.21 (1.15–1.27); CV mortality RR 1.50; T2D dose-response 1.12; Lancet Series concurs	Low–Very low (observational; GRADE downgraded) but consistent, dose-responsive	Conditional recommendation (to minimise UPFs)
Adequate/higher protein (≥0.8, ~1.0–1.6 g/kg/day) + resistance exercise → muscle mass/function in older adults	RCT/observational syntheses: benefit on lean mass with anabolic/catabolic stressors; effect on strength/function inconsistent	Low–Moderate	Conditional recommendation
Caloric restriction (non-obese) → healthspan/biomarkers	CALERIE: improved cardiometabolic risk, biological-ageing markers (surrogate); no human mortality benefit shown; malnutrition/lean-mass concerns	Low (surrogate, short-term)	Conditional / research in non-obese
Time-restricted eating → cardiometabolic surrogates	Scoping review (81 studies) + meta-analyses: improved weight, insulin sensitivity, lipids, BP; no hard-outcome or longevity data	Low	Conditional recommendation (surrogate benefit only)
Vitamin D3 2000 IU/day → cancer/CVD/mortality	VITAL (n=25,871): no reduction in total cancer incidence, major CVD, or all-cause mortality; possible cancer-mortality signal in meta-analyses	High (for null primary endpoints)	Recommend against routine use for longevity
Marine omega-3 1 g/day → major CVD	VITAL: no reduction in composite major CVD; reduced total/fatal MI (secondary); benefit greatest in low fish intake	Moderate–High	Conditional (not for primary longevity)
NAD⁺ precursors (NR/NMN) → healthspan outcomes	33 human trials: reliable NAD⁺ target engagement, good short-term tolerability; functional/metabolic outcomes heterogeneous, often null	Very low for clinical benefit	Only in research
Spermidine → cognition/ageing outcomes	Sparse small human trials; predominantly preclinical/observational	Very low	Only in research
Protein/amino-acid (methionine) restriction, mTOR modulation → human longevity	Rodent lifespan data; human data limited to metabolic surrogates; lean-mass/frailty risk	Very low for human longevity	Recommend against outside research

Cross-cutting GRADE considerations: Dietary-pattern trials carry unavoidable risk of bias (open-label, adherence, co-interventions) and indirectness (mostly higher-CV-risk or older populations rather than healthy midlife longevity clients). Cohort evidence (plant-based, UPFs, fibre) has residual confounding and moderate–high heterogeneity (I² frequently >50%). Restriction/supplement trials suffer imprecision (small n, wide CIs) and rely on surrogate endpoints. Publication bias is a specific concern for supplement and TRE literature.

---

4. Patient selection and indications

Who is likely to benefit (offer dietary-pattern optimisation):

• Middle-aged adults with elevated cardiometabolic risk (raised LDL-C/apoB, hypertension, dysglycaemia, central adiposity, metabolic syndrome, high QRISK).
• Overweight/obese adults, including older adults, where CR-based weight loss reduces inflammation, improves glycaemia and lowers CVD/frailty risk.
• Older adults at risk of sarcopenia/frailty — for protein optimisation plus resistance exercise.
• Any adult with high habitual ultra-processed food intake or fibre intake <20 g/day.

Clinical scenario nuances:

• High cardiometabolic risk midlife adult: strongest expected absolute benefit from Mediterranean/low-fat patterns.
• Older frail patient: prioritise protein adequacy and lean-mass preservation; avoid aggressive restriction.
• Athlete seeking performance vs longevity: protein needs and energy availability differ; longevity-motivated protein restriction may impair performance and lean mass.

Exclusion criteria / high-risk groups (avoid or specialist input for restrictive or supplement interventions):

• Underweight (BMI <18.5), unintentional weight loss, frailty or diagnosed sarcopenia — avoid CR/IF/protein restriction.
• History of eating disorder — avoid all restriction-based protocols.
• Type 1 or insulin/sulfonylurea-treated diabetes — fasting/TRE risks hypoglycaemia; requires diabetes-team involvement.
• Pregnancy and breastfeeding — avoid fasting, CR and unproven supplements.
• Advanced CKD or hepatic impairment — individualise protein; avoid unstudied supplements.
• Children, adolescents and adults >80 or with multimorbidity/polypharmacy — caution.

Regulatory and ethical status:

• On-label / guideline-based: whole-diet patterns (Mediterranean, low-fat, plant-based, fibre/whole grains, minimising UPFs) — aligned with NICE, AHA and NHS Eatwell guidance.
• Off-label / supplement (food, not medicine): NR, NMN, spermidine are marketed as supplements in the UK, not licensed medicines for any anti-ageing indication; efficacy for longevity is unproven — only in research or with explicit informed consent that benefit is unestablished.
• Research-only framing recommended for: CR in non-obese individuals for longevity, methionine/amino-acid restriction, NAD⁺ precursors, spermidine, and any regimen justified solely by surrogate biomarker change.

---

5. Assessment and baseline work-up

History and examination:

• Full dietary history (pattern, UPF fraction, fibre, protein distribution, alcohol, meal timing), weight trajectory, GI symptoms, appetite.
• Cardiometabolic risk factors, medications (especially glucose-lowering, anticoagulants, antihypertensives), supplement use.
• Eating-disorder screen before any restrictive protocol.
• Anthropometry: weight, height, BMI, waist circumference; consider body composition (DEXA/BIA) and grip strength/gait speed in older adults.

Validated tools:

• Mediterranean diet adherence score (e.g. MEDAS/PREDIMED) to quantify baseline and track change.
• Frailty and sarcopenia screening in older adults (e.g. SARC-F, grip strength, gait speed, Clinical Frailty Scale).
• QRISK3 / lipid-based CV risk estimation.

Baseline investigations (tailored):

• Lipid profile (consider apoB/Lp(a)), HbA1c/fasting glucose, U&E/eGFR, LFTs, FBC, TFTs.
• 25-hydroxyvitamin D where deficiency suspected (treat deficiency per NICE, not for longevity per se).
• Nutritional status markers if intake is restrictive: ferritin, B12/folate, calcium/phosphate, magnesium.

Ageing biomarkers (optional, research/monitoring context only): epigenetic clocks, leukocyte telomere length, inflammatory markers (hs-CRP, IL-6). Document if used, but do not use them as sole justification for treatment or to claim clinical benefit — the surrogate-to-outcome link is not validated.

Risk stratification: stratify separately for (a) expected benefit (higher for those with modifiable cardiometabolic risk/high UPF/low fibre) and (b) harm risk (higher with frailty, low BMI, insulin/sulfonylurea use, ED history, CKD).

Baseline documentation: weight/waist/body composition, adherence score, cardiometabolic labs, medication list, and clearly recorded informed consent for any off-label/research-only element.

---

6. Dosing regimens and practical implementation

Regimens supported by robust human data

Mediterranean pattern (first-line): predominance of vegetables, fruit, wholegrain cereals, pulses, nuts, olive oil as principal fat; moderate fish and fermented dairy; low red/processed meat; wine optional and not to be recommended for abstainers or those with alcohol-related risk. Target high adherence (MEDAS ≥9). Strong evidence for mortality/CVD reduction in higher-risk adults (Karam et al., 2023).

Low-fat pattern: an evidence-equivalent alternative for mortality/MI reduction where preferred by the patient (Karam et al., 2023).

Dietary fibre and whole grains: target ≥25–29 g/day total fibre, with additional benefit at higher intakes; emphasise wholegrain, cereal, vegetable and legume sources; increase gradually to limit GI intolerance (Reynolds et al., 2019).

Minimise ultra-processed foods: replace UPFs with minimally processed foods; no threshold established but consistent dose-response harm (Lane et al., 2024).

Protein in older adults: ~1.0–1.6 g/kg/day (above the 0.8 g/kg RDA), distributed across meals (~25–30 g/meal, leucine-rich), combined with resistance training to preserve lean mass; higher end for those under catabolic stress or in weight loss. Benefit on mass more consistent than on strength/function (Campbell et al., 2023; Murphy et al., 2023).

Weight loss in overweight/obese adults: modest energy restriction with adequate protein and resistance exercise to protect lean mass.

Regimens with human surrogate-endpoint data only (use with caution, informed consent)

Time-restricted eating: common protocols 16:8 or 14:10; earlier eating window (earlier day) associated with better glycaemic/cardiometabolic surrogates. No hard-outcome or longevity data; monitor nutritional adequacy and protein intake, especially in older adults (Minari & Pisani, 2026; AHA statement, 2025). Not recommended in frailty, low BMI, ED history, or insulin/sulfonylurea therapy without specialist input.

Caloric restriction / intermittent fasting for cardiometabolic surrogates: reasonable in overweight/obese adults as a weight-management tool; not evidence-based for longevity in non-obese, lean individuals (CALERIE = surrogate/short-term).

Regimens extrapolated from early-phase/preclinical data — require caution (research/off-label)

• NAD⁺ precursors (NR, NMN): trials commonly use NR ~250–1000 mg/day or NMN ~250–900 mg/day; reliably raise NAD⁺ and are short-term tolerable, but clinical efficacy for ageing outcomes is unproven — position as only in research (Freeberg et al., 2023; Gallagher & Emmanuel, 2026). No outcome data support intravenous NAD⁺.
• Spermidine, methionine/amino-acid restriction, mTOR-directed dietary strategies: no adequate human longevity data; do not routinely offer outside trials.

---

7. Monitoring, safety and follow-up

Clinical monitoring:

• Weight, waist, BMI and (where available) body composition and grip strength/gait speed — critical to detect unintended lean-mass or weight loss, especially in older adults on restriction protocols.
• Symptoms: fatigue, dizziness, hypoglycaemia, GI intolerance (fibre), disordered-eating behaviours.

Laboratory monitoring:

• Lipids, HbA1c/glucose, U&E/eGFR, LFTs at baseline and periodically (e.g. 3–6 months then annually) to demonstrate cardiometabolic response.
• Micronutrients (B12, folate, ferritin, vitamin D, calcium/magnesium) if intake is restrictive or plant-exclusive.
• In diabetes: intensified glucose monitoring when initiating TRE/IF, with pre-emptive reduction of hypoglycaemic agents.

Ageing biomarkers: may be tracked for research/engagement but interpret cautiously; changes do not confirm clinical benefit.

Suggested timepoints: short-term 4–6 weeks (tolerability, adherence, hypoglycaemia); medium-term 3–6 months (cardiometabolic labs, weight/body composition); long-term annually (sustained adherence, functional status, safety labs).

Adverse effects:

• Restriction strategies (CR/IF/TRE): hunger, irritability, headache, hypoglycaemia (in treated diabetes), and risk of inadequate protein/micronutrient intake and lean-mass loss; potential to precipitate disordered eating.
• High-fibre transition: bloating, flatulence — mitigate with gradual increase and fluids.
• NAD⁺ precursors: generally well tolerated short-term; long-term safety unknown (Freeberg et al., 2023).
• Supplements generally: unregulated quality; interaction and contamination risk.

Actions for abnormal findings: unintended weight/lean-mass loss, frailty progression, hypoglycaemia, or biochemical deficiency → relax or stop restriction, optimise protein/energy, correct deficiency, and refer as needed.

Interactions:

• IF/TRE/CR + insulin or sulfonylureas → hypoglycaemia (dose adjust; involve diabetes team).
• High vitamin K from leafy greens ↔ warfarin (maintain consistency; INR monitoring).
• Grapefruit and various foods ↔ CYP-metabolised drugs.
• Marine omega-3 at high dose ↔ possible bleeding risk with anticoagulants/antiplatelets; possible atrial fibrillation signal at high doses.

Special populations:

• Pregnancy/breastfeeding: avoid fasting, CR and unproven supplements; follow standard antenatal nutrition guidance.
• Renal impairment: individualise protein; avoid unstudied supplements; monitor electrolytes.
• Hepatic impairment: caution with supplements; monitor LFTs.
• Frailty/extremes of age: prioritise energy/protein adequacy over restriction.

---

8. Contraindications and cautions

Absolute contraindications (to restriction-based protocols — CR/IF/TRE/protein or amino-acid restriction):

• Active or historical eating disorder.
• Underweight (BMI <18.5) or ongoing unintentional weight loss.
• Pregnancy and breastfeeding.
• Established frailty or clinically significant sarcopenia (for protein/energy restriction).

Relative contraindications / specialist input required:

• Insulin- or sulfonylurea-treated diabetes (hypoglycaemia risk with fasting/TRE).
• Advanced CKD or hepatic impairment.
• Older adults with multimorbidity/polypharmacy.
• Any unlicensed supplement in patients on anticoagulants, immunosuppressants or with organ impairment.

Where harm likely outweighs benefit with current evidence:

• Routine vitamin D or omega-3 supplementation for longevity/CVD/mortality prevention in replete, average-risk adults (VITAL null primary endpoints).
• CR or protein/methionine restriction for longevity in lean, non-obese or older adults (surrogate/preclinical only, lean-mass risk).
• NAD⁺ precursors, spermidine or IV NAD⁺ marketed as proven anti-ageing therapy.

---

9. Practical management scenarios (CKS-style)

Scenario A — Middle-aged adult with multiple cardiometabolic risk factors

Recommendation: Offer (Strong). Highest-quality, hard-outcome evidence applies to this group.

1. Assessment: cardiometabolic labs (lipids/apoB, HbA1c, BP, waist), QRISK3, dietary/UPF/fibre history, MEDAS score.
2. Shared decision-making: discuss Mediterranean or low-fat pattern as evidence-equivalent options (mortality/MI reduction); set fibre ≥25–29 g/day and UPF-reduction goals.
3. Initiation: structured Mediterranean prescription; gradual fibre increase; align with any statin/antihypertensive therapy.
4. Monitoring: 3–6-monthly lipids/HbA1c/weight/waist; adherence score.
5. Escalate/refer: if targets unmet, coordinate with GP for pharmacotherapy; refer to dietitian for adherence support.

Scenario B — Older, frail patient with multimorbidity

Recommendation: Offer protein optimisation + resistance exercise (Conditional); Avoid CR/IF/TRE/protein restriction.

1. Assessment: sarcopenia/frailty screen (grip strength, gait speed, SARC-F, CFS), body composition, renal function, weight trajectory.
2. Shared decision-making: emphasise lean-mass preservation; explain that longevity-marketed restriction may cause harm here.
3. Initiation: protein ~1.0–1.6 g/kg/day distributed across meals (leucine-rich), Mediterranean-style whole foods, structured resistance training; correct deficiencies.
4. Monitoring: weight/lean mass, grip strength, renal function; watch for anorexia/weight loss.
5. Escalate/refer: dietitian/geriatrics if weight loss, worsening frailty, or intake inadequate.

Scenario C — Patient under specialist care wanting nutrition as an adjunct

Recommendation: Consider as adjunct with informed consent; coordinate with the specialist team.

1. Assessment: reconcile medications and diagnoses; identify interaction risks (anticoagulants, glucose-lowering, immunosuppressants).
2. Shared decision-making: position diet-pattern optimisation as complementary; clearly flag any supplement (NAD⁺ precursor etc.) as unproven/off-label if the patient requests it.
3. Initiation: guideline-based dietary pattern; avoid introducing unlicensed supplements that may interact; if fasting/TRE desired in diabetes, coordinate hypoglycaemic-agent adjustment with the diabetes team.
4. Monitoring: joint monitoring plan; relevant safety labs.
5. Escalate/refer: stop and liaise with the specialist for any adverse interaction or deterioration.

---

10. Research gaps and future directions

Key uncertainties:

• Whether dietary-pattern mortality benefits demonstrated in higher-CV-risk populations translate to healthy midlife longevity clients (indirectness).
• Whether CR/IF/TRE affect hard longevity outcomes in humans, or only surrogate cardiometabolic markers; optimal window, timing and long-term adherence.
• Optimal protein intake balancing longevity signals (lower intake) against sarcopenia/frailty prevention (higher intake) — the central protein paradox.
• Whether NAD⁺ precursors, spermidine, or amino-acid/methionine restriction confer any clinically meaningful human benefit despite target engagement.
• Validity of epigenetic clocks and telomere length as surrogates predicting clinical outcomes.

Priority research questions: long-term RCTs with hard endpoints for TRE and CR; dose-finding and clinically meaningful endpoint trials for NAD⁺ precursors; protein-titration RCTs stratified by age/frailty; UPF-reduction interventional trials.

Where practice should be limited to trials/registries: CR for longevity in non-obese adults; methionine/amino-acid restriction; NAD⁺ precursors and spermidine; any intervention justified solely by ageing-biomarker change. Clinics offering these should do so within a research or registry framework with explicit informed consent that clinical benefit is unproven.

 

Footnote

How the evidence supports the summary and key caveats:

– The strongest recommendations rest on RCT-level and large-cohort mortality data. The Mediterranean and low-fat dietary-programme recommendations derive from the BMJ network meta-analysis of 40 RCTs (n≈35,548), which found moderate-certainty mortality and MI reductions; the general-population Mediterranean signal is reinforced by a 54-cohort meta-analysis (n≈1.83M). Fibre/whole-grain guidance draws on the Lancet carbohydrate-quality series and cohort meta-analyses showing linear dose-response mortality reductions. Plant-based pattern benefit is cohort-based and graded lower.[1][12][3][4][13][2]

– Surrogate-only and preclinical data are deliberately quarantined. CR/IF/TRE effects in humans remain confined to cardiometabolic surrogates (CALERIE, scoping/meta-analytic TRE data) with no hard-outcome or longevity evidence; NAD⁺ precursors show target engagement but heterogeneous/null clinical outcomes; protein/methionine restriction longevity data are rodent-only. These are flagged “only in research” or “recommend against outside research.”[7][14][9][15][16][10][17][18][11][19]

– Two safety-critical negatives are preserved: VITAL demonstrated no all-cause mortality, cancer-incidence, or major-CVD benefit from vitamin D3 2000 IU/day, and no major-CVD reduction from 1 g/day omega-3 (secondary MI signal only) — so routine supplementation for longevity is discouraged. The vitamin D telomere finding is explicitly treated as a surrogate, not a clinical endpoint.[20][21][22][8]

– The protein paradox is left unresolved rather than harmonised: longevity signals favour moderate protein while sarcopenia/frailty prevention favours higher intake (~1.0–1.6 g/kg/day) with resistance exercise — the document preserves this genuine tension and ties restriction contraindications to frailty, low BMI, and eating-disorder history.[23][24][25][11]

References

1. Comparison of Seven Popular Structured Dietary Programmes and Risk of Mortality and Major Cardiovascular Events in Patients at Increased Cardiovascular Risk: Systematic Review and Network Meta-Analysis. Karam G, Agarwal A, Sadeghirad B, et al. BMJ (Clinical Research Ed.). 2023;380:e072003. doi:10.1136/bmj-2022-072003.
2. Associations Between Plant-Based Dietary Patterns and Risks of Type 2 Diabetes, Cardiovascular Disease, Cancer, and Mortality – A Systematic Review and Meta-Analysis. Wang Y, Liu B, Han H, et al. Nutrition Journal. 2023;22(1):46. doi:10.1186/s12937-023-00877-2.
3. Carbohydrate Quality and Human Health: A Series of Systematic Reviews and Meta-Analyses. Reynolds A, Mann J, Cummings J, et al. Lancet (London, England). 2019;393(10170):434-445. doi:10.1016/S0140-6736(18)31809-9.
4. Dietary Fiber Intake and All-Cause and Cause-Specific Mortality: An Updated Systematic Review and Meta-Analysis of Prospective Cohort Studies. Ramezani F, Pourghazi F, Eslami M, et al. Clinical Nutrition (Edinburgh, Scotland). 2024;43(1):65-83. doi:10.1016/j.clnu.2023.11.005.
5. Ultra-Processed Food Exposure and Adverse Health Outcomes: Umbrella Review of Epidemiological Meta-Analyses. Lane MM, Gamage E, Du S, et al. BMJ (Clinical Research Ed.). 2024;384:e077310. doi:10.1136/bmj-2023-077310.
6. Ultra-Processed Foods and Human Health: The Main Thesis and the Evidence. Monteiro CA, Louzada ML, Steele-Martinez E, et al. Lancet (London, England). 2025;406(10520):2667-2684. doi:10.1016/S0140-6736(25)01565-X.
7. Effects of Intermittent Fasting on Health, Aging, and Disease. de Cabo R, Mattson MP. The New England Journal of Medicine. 2019;381(26):2541-2551. doi:10.1056/NEJMra1905136.
8. Vitamin D3 and Marine Ω-3 Fatty Acids Supplementation and Leukocyte Telomere Length: 4-Year Findings From the VITamin D and OmegA-3 TriaL (VITAL) Randomized Controlled Trial. Zhu H, Manson JE, Cook NR, et al. The American Journal of Clinical Nutrition. 2025;122(1):39-47. doi:10.1016/j.ajcnut.2025.05.003.
9. Time-Restricted Eating in Metabolic and Clinical Health: A Current Evidence and Mechanistic Insights. Minari TP, Pisani LP. The Journal of Nutrition. 2026;156(7):101269. doi:10.1016/j.tjnut.2025.101269.
10. NAD⁺ Supplementation for Anti-Aging and Wellness: A PRISMA-guided Systematic Review of Preclinical and Clinical Evidence. Gallagher C, Emmanuel OO. Ageing Research Reviews. 2026;116:103057. doi:10.1016/j.arr.2026.103057.
11. Protein-Restricted Diets and Their Impact on Metabolic Health and Aging. Kim SQ, Spann RA, Hill CM, et al. Annual Review of Nutrition. 2025;. doi:10.1146/annurev-nutr-121624-114918.
12. Adherence to the Mediterranean Diet and All-Cause Mortality: A Systematic Review and Meta-Analysis Within the Italian National Guidelines “La Dieta Mediterranea”. Nucci D, Ragusa FS, Mazza E, et al. Nutrition (Burbank, Los Angeles County, Calif.). 2026;147:113189. doi:10.1016/j.nut.2026.113189.
13. Total and Different Dietary Fiber Subtypes and the Risk of All-Cause, Cardiovascular, and Cancer Mortality: A Dose-Response Meta-Analysis of Prospective Cohort Studies. Mirrafiei A, Jayedi A, Shab-Bidar S. Food & Function. 2023;14(24):10667-10680. doi:10.1039/d2fo04024g.
14. Impact of Geroscience on Therapeutic Strategies for Older Adults With Cardiovascular Disease: JACC Scientific Statement. Forman DE, Kuchel GA, Newman JC, et al. Journal of the American College of Cardiology. 2023;82(7):631-647. doi:10.1016/j.jacc.2023.05.038.
15. Role of Circadian Health in Cardiometabolic Health and Disease Risk: A Scientific Statement From the American Heart Association. Knutson KL, Dixon DD, Grandner MA, et al. Circulation. 2025;152(21):e408-e419. doi:10.1161/CIR.0000000000001388.
16. Dietary Supplementation With NAD+-Boosting Compounds in Humans: Current Knowledge and Future Directions. Freeberg KA, Udovich CC, Martens CR, Seals DR, Craighead DH. The Journals of Gerontology. Series A, Biological Sciences and Medical Sciences. 2023;78(12):2435-2448. doi:10.1093/gerona/glad106.
17. Nicotinamide Adenine Dinucleotide in Aging Biology: Potential Applications and Many Unknowns. Bhasin S, Seals D, Migaud M, Musi N, Baur JA. Endocrine Reviews. 2023;44(6):1047-1073. doi:10.1210/endrev/bnad019.
18. Dietary Protein and Amino Acid Restriction: Roles in Metabolic Health and Aging-Related Diseases. Wang D, Ye J, Shi R, et al. Free Radical Biology & Medicine. 2022;178:226-242. doi:10.1016/j.freeradbiomed.2021.12.009.
19. Dietary Restriction and Nutrient Balance in Aging. Santos J, Leitão-Correia F, Sousa MJ, Leão C. Oxidative Medicine and Cellular Longevity. 2016;2016:4010357. doi:10.1155/2016/4010357.
20. Effect of Vitamin D Supplementation, Omega-3 Fatty Acid Supplementation, or a Strength-Training Exercise Program on Clinical Outcomes in Older Adults. Bischoff-Ferrari HA, Vellas B, Rizzoli R, et al. JAMA. 2020;324(18):1855-1868. doi:10.1001/jama.2020.16909.
21. Principal Results of the VITamin D and OmegA-3 TriaL (VITAL) and Updated Meta-Analyses of Relevant Vitamin D Trials. Manson JE, Bassuk SS, Buring JE. The Journal of Steroid Biochemistry and Molecular Biology. 2020;198:105522. doi:10.1016/j.jsbmb.2019.105522.
22. Vitamin D, Marine N-3 Fatty Acids, and Primary Prevention of Cardiovascular Disease Current Evidence. Manson JE, Bassuk SS, Cook NR, et al. Circulation Research. 2020;126(1):112-128. doi:10.1161/CIRCRESAHA.119.314541.
23. Nutritional Interventions: Dietary Protein Needs and Influences on Skeletal Muscle of Older Adults. Campbell WW, Deutz NEP, Volpi E, Apovian CM. The Journals of Gerontology. Series A, Biological Sciences and Medical Sciences. 2023;78(Suppl 1):67-72. doi:10.1093/gerona/glad038.
24. Nutrition Strategies to Counteract Sarcopenia: A Focus on Protein, LC N-3 PUFA and Precision Nutrition. Murphy CH, McCarthy SN, Roche HM. The Proceedings of the Nutrition Society. 2023;82(3):419-431. doi:10.1017/S0029665123003555.
25. Nutrition in the Prevention and Treatment of Skeletal Muscle Ageing and Sarcopenia: A Single Nutrient, a Whole Food and a Whole Diet Approach. Granic A, Sayer AA, Cooper R, Robinson SM. The Proceedings of the Nutrition Society. 2024;:1-16. doi:10.1017/S0029665124007432.